Physician profile
Cameron Whitler
NPI 1265963797
$16,278.91
in general payments reported to CMS, 2019-2025
27 companies · $472 in 2025
The $472 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $610 · 2021: $1,393 · 2022: $2,391 · 2023: $11K · 2024: $883 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $8,500 · Food and Beverage: $3,370 · Entertainment: $14.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $8,500.00 |
| Food and Beverage | $3,370.39 |
| Entertainment | $14.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $6,143.96 | 2021-2025 | Diamondback Coronary, Ensite, Dragonfly Opstar |
| Medtronic, INC. | $4,752.66 | 2021-2025 | Corevalve Evolut R, Hawkone, In.Pact Admiral |
| Boston Scientific Corporation | $842.31 | 2020-2024 | Avvigo Guidance System, Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $702.27 | 2020-2023 | Lifevest |
| Abiomed | $672.49 | 2022-2025 | Impella |
| Amgen INC. | $597.87 | 2021-2023 | Repatha |
| Shockwave Medical, INC | $321.85 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Philips North America LLC | $286.66 | 2020-2025 | (Bq9) Coronary Ivus, (P77) Azurion 7 M20, Igt Devices Systems Undivided |
| E.R. Squibb & Sons, L.L.C. | $248.97 | 2021-2023 | Camzyos |
| Penumbra, INC. | $245.49 | 2022-2023 | Indigo System |
| Teleflex LLC | $165.46 | 2023 | Guideliner |
| Genzyme Corporation | $149.99 | 2022 | |
| W. L. Gore & Associates, INC. | $134.67 | 2021 | |
| Medtronic Vascular, INC. | $132.96 | 2020 | |
| Edwards Lifesciences Corporation | $126.06 | 2021-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cordis US Corp. | $118.94 | 2023 | Mynx Control, Zephyr |
| Opsens INC. | $112.41 | 2022-2023 | Optowire |
| Cardiovascular Systems INC. | $106.71 | 2020 | |
| Chiesi USA, INC. | $88.59 | 2022-2023 | Kengreal |
| Cathworks, INC. | $84.12 | 2023 | Ffrangio |
| Kestra Medical Technology Services, INC. | $76.59 | 2022 | |
| Merck Sharp & Dohme LLC | $70.65 | 2022 | |
| Novartis Pharmaceuticals Corporation | $23.34 | 2022 | |
| Novo Nordisk INC | $21.68 | 2021 | |
| Janssen Scientific Affairs, LLC | $20.10 | 2023 | Xarelto |
| Terumo Medical Corporation | $17.06 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cameron Whitler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.